Edge Therapeutics is a clinical-stage biotechnology company that discovers and develops hospital-based therapies for the management of acute, critical care conditions. Co.'s initial product candidates target rare, acute, neurological and other conditions. EG-1962, Co.'s product candidate, is for the management of aneurysmal subarachnoid hemorrhage, which is bleeding around the brain due to a ruptured brain aneurysm. In addition to EG-1962, Co. is developing EG-1964, as a prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain. Co. is also developing EG-1965, for the prevention of post-operative atrial fibrillation. The EDGE average annual return 10 years is shown above.
The Average Annual Return on the EDGE average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether EDGE average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the EDGE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
